Cocrystal Pharma, Inc.COCPNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-24.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-24.9%/yr
Quarterly compound
Percentile
P64
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 13.79% |
| Q2 2025 | 0.51% |
| Q1 2025 | -15.79% |
| Q4 2024 | -35.28% |
| Q3 2024 | 57.89% |
| Q2 2024 | -5.63% |
| Q1 2024 | -13.65% |
| Q4 2023 | -24.34% |
| Q3 2023 | 20.22% |
| Q2 2023 | 27.74% |
| Q1 2023 | -0.91% |
| Q4 2022 | -33.32% |
| Q3 2022 | 32.51% |
| Q2 2022 | 3.15% |
| Q1 2022 | -4.58% |
| Q4 2021 | -24.40% |
| Q3 2021 | 45.40% |
| Q2 2021 | 9.47% |
| Q1 2021 | -9.15% |
| Q4 2020 | 14.01% |
| Q3 2020 | -44.72% |
| Q2 2020 | 78.05% |
| Q1 2020 | -10.03% |
| Q4 2019 | 3.52% |
| Q3 2019 | 16.37% |
| Q2 2019 | -20.56% |
| Q1 2019 | 10.71% |
| Q4 2018 | 25.53% |
| Q3 2018 | -6.02% |
| Q2 2018 | -14.87% |
| Q1 2018 | 63.46% |
| Q4 2017 | 1.53% |
| Q3 2017 | 1403.64% |
| Q2 2017 | -105.24% |
| Q1 2017 | 105.88% |
| Q4 2016 | 356.28% |
| Q3 2016 | -110.84% |
| Q2 2016 | -7.83% |
| Q1 2016 | -30.42% |
| Q4 2015 | 99.23% |